Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C25H26N8O |
| Molecular Weight | 454.5269 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC1=C(C=CC(=C1)C(N)=O)N2N=C(C(C)C)C3=C2N=CC=C3N4C=NC(=C4)C5=CN(C)N=C5
InChI
InChIKey=NVVPMZUGELHVMH-UHFFFAOYSA-N
InChI=1S/C25H26N8O/c1-5-16-10-17(24(26)34)6-7-20(16)33-25-22(23(30-33)15(2)3)21(8-9-27-25)32-13-19(28-14-32)18-11-29-31(4)12-18/h6-15H,5H2,1-4H3,(H2,26,34)
| Molecular Formula | C25H26N8O |
| Molecular Weight | 454.5269 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 12:07:05 UTC 2023
by
admin
on
Sat Dec 16 12:07:05 UTC 2023
|
| Record UNII |
PLO044MUDZ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C134448
Created by
admin on Sat Dec 16 12:07:05 UTC 2023 , Edited by admin on Sat Dec 16 12:07:05 UTC 2023
|
PRIMARY | |||
|
DB14876
Created by
admin on Sat Dec 16 12:07:05 UTC 2023 , Edited by admin on Sat Dec 16 12:07:05 UTC 2023
|
PRIMARY | |||
|
TAS-116
Created by
admin on Sat Dec 16 12:07:05 UTC 2023 , Edited by admin on Sat Dec 16 12:07:05 UTC 2023
|
PRIMARY | Description: TAS-116 showed activity against orthotopically transplanted NCI-H1975 lung tumors. Together, these data suggest that TAS-116 has a potential to maximize antitumor activity while minimizing adverse effects such as visual disturbances that are observed with other compounds of this class. For the detailed information of TAS-116, the solubility of TAS-116 in water, the solubility of TAS-116 in DMSO, the solubility of TAS-116 in PBS buffer, the animal experiment (test) of TAS-116, the cell expriment (test) of TAS-116, the in vivo, in vitro and clinical trial test of TAS-116, the EC50, IC50, and affinity, of TAS-116, For the detailed information of TAS-116, the solubility of TAS-116 in water, the solubility of TAS-116 in DMSO, the solubility of TAS-116 in PBS buffer, the animal experiment (test) of TAS-116, the cell expriment (test) of TAS-116, the in vivo, in vitro and clinical trial test of TAS-116, the EC50, IC50, and affinity, of TAS-116, Please contact DC Chemicals. | ||
|
67501411
Created by
admin on Sat Dec 16 12:07:05 UTC 2023 , Edited by admin on Sat Dec 16 12:07:05 UTC 2023
|
PRIMARY | |||
|
300000038118
Created by
admin on Sat Dec 16 12:07:05 UTC 2023 , Edited by admin on Sat Dec 16 12:07:05 UTC 2023
|
PRIMARY | |||
|
PLO044MUDZ
Created by
admin on Sat Dec 16 12:07:05 UTC 2023 , Edited by admin on Sat Dec 16 12:07:05 UTC 2023
|
PRIMARY | |||
|
1260533-36-5
Created by
admin on Sat Dec 16 12:07:05 UTC 2023 , Edited by admin on Sat Dec 16 12:07:05 UTC 2023
|
PRIMARY | |||
|
11079
Created by
admin on Sat Dec 16 12:07:05 UTC 2023 , Edited by admin on Sat Dec 16 12:07:05 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Oral administration of TAS-116 led to tumor shrinkage in human tumor xenograft mouse models accompanied by depletion of multiple HSP90 clients, demonstrating that the inhibition of HSP90.ALPHA. and .BETA. alone was sufficient to exert antitumor activity in certain tumor models. One of the most notable HSP90-related adverse events universally observed to differing degrees in the clinical setting is visual disturbance. A two-week administration of the isoxazole resorcinol NVP-AUY922, an HSP90 inhibitor, caused marked degeneration and disarrangement of the outer nuclear layer of the retina and induced photoreceptor cell death in rats. In contrast, TAS-116 did not produce detectable photoreceptor injury in rats, probably due to its lower distribution in retinal tissue. Importantly, in a rat model, the antitumor activity of TAS-116 was accompanied by a higher distribution of the compound in subcutaneously xenografted NCI-H1975 non-small cell lung carcinoma tumors than in retina. Moreover, TAS-116 showed activity against orthotopically transplanted NCI-H1975 lung tumors.
|
